DMK Pharmaceuticals Corporation
DMKPQOTCHealthcare
$0.00
+$0.00(+0.00%)
Market Cap$1010
P/E Ratio—
52W High$0.001
52W Low$0.00001
DMK Pharmaceuticals Corporation (DMKPQ) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · DMKPQ · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 | 2018-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $4.76M | $2.21M | $2.78M | $22.11M | $15.09M |
| Cost of Revenue | $7.65M | $6.87M | $6.33M | $15.68M | $12.90M |
| Gross Profit | ($2.90M) | ($4.66M) | ($3.55M) | $6.44M | $2.19M |
| Gross Margin %(computed) | -60.93% | -211.14% | -127.87% | 29.10% | 14.51% |
| Operating Expenses | |||||
| R&D Expenses | $10.38M | $11.26M | $8.04M | $11.03M | $19.69M |
| G&A Expenses | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Total Operating Expenses | $22.16M | $27.41M | $28.13M | $36.44M | $42.54M |
| Operating Income | ($25.06M) | ($32.07M) | ($31.68M) | ($30.00M) | ($40.35M) |
| Operating Margin %(computed) | -526.88% | — | — | -135.67% | -267.47% |
| Interest Income | $0.04M | $0.00M | $0.00M | $0.00M | $0.25M |
| Interest Expense | $0.00M | $0.01M | $0.00M | $0.12M | $0.16M |
| Income Before Tax | ($26.20M) | ($34.60M) | ($35.84M) | ($28.16M) | ($40.28M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | ($0.64M) | ($1.27M) |
| Net Income | ($26.48M) | ($45.83M) | ($49.39M) | ($27.51M) | ($39.01M) |
| Net Margin %(computed) | -556.72% | — | — | -124.41% | -258.55% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-12.37 | $-22.25 | $-44.57 | $-36.16 | $-69.86 |
| Wtd Avg Shares | 2.14M | 2.06M | 1.11M | 0.76M | 0.56M |
| EBITDA | ($23.58M) | ($30.63M) | ($33.51M) | ($25.07M) | ($37.02M) |
| EBITDA Margin %(computed) | -495.69% | — | — | -113.37% | -245.37% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more DMK Pharmaceuticals Corporation data
About DMK Pharmaceuticals Corporation (DMKPQ) Income Statement
DMK Pharmaceuticals Corporation (DMKPQ) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2022, DMKPQ reported revenue of $0.00B, gross profit of ($0.00B) (gross margin -60.93%), and net income of ($0.03B) — a net profit margin of -556.72%.
Frequently asked questions
DMKPQ · 4 questionsDMK Pharmaceuticals Corporation (DMKPQ) reported revenue of $0.00B for 2022, up 115.3% year-over-year.
DMKPQ revenueDMKPQ salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08